H.R. 2547 - Surrogate Endpoint Improvement and Utilization Act of 2015
- Sponsor:
- Cathy McMorris Rodgers
- Summary:
- To amend the Federal Food, Drug, and Cosmetic Act to provide for the development of accelerated approval development plans for investigational drugs and biological products. (by CRS)
- Status:
- The bill has been referred to committee.
Surrogate Endpoint Improvement and Utilization Act of 2015
H.R. 2547 — 114th Congress (2015–2016)
- Summary
- To amend the Federal Food, Drug, and Cosmetic Act to provide for the development of accelerated approval development plans for investigational drugs and biological products. (by CRS)
- Learn More
- At OpenCongress
- Title
- To amend the Federal Food, Drug, and Cosmetic Act to provide for the development of accelerated approval development plans for investigational drugs and biological products.
- Other Titles
- Surrogate Endpoint Improvement and Utilization Act of 2015
- Surrogate Endpoint Improvement and Utilization Act of 2015
- Sponsor
- Cathy McMorris Rodgers
- Co-Sponsors
- Subjects
- Health
- Drug safety, medical device, and laboratory regulation
- Related Bills
- Major Actions
Introduced 5/21/2015 Referred to Committee - Bill History
-
There have been no votes on this bill.
Action Date Description Introduced 5/21/2015 5/21/2015 Referred to the House Committee on Energy and Commerce. 5/21/2015 Introduced in House 5/22/2015 Referred to the Subcommittee on Health. Number Sponsor Date Offered Status
MapLight did not identify any interest groups that took a position on this vote.
You may be able to explore campaign contributions data if you add interest groups.
Contributions data source: OpenSecrets.org